1. Home
  2. PGZ vs BNR Comparison

PGZ vs BNR Comparison

Compare PGZ & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$10.09

Market Cap

67.1M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$8.08

Market Cap

76.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGZ
BNR
Founded
2012
2014
Country
United States
China
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
76.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PGZ
BNR
Price
$10.09
$8.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.2K
25.3K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
12.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.32
$3.11
52 Week High
$10.64
$41.72

Technical Indicators

Market Signals
Indicator
PGZ
BNR
Relative Strength Index (RSI) 59.51 37.97
Support Level $10.01 $8.04
Resistance Level $10.18 $9.90
Average True Range (ATR) 0.13 0.83
MACD 0.02 0.31
Stochastic Oscillator 76.92 46.26

Price Performance

Historical Comparison
PGZ
BNR

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: